Viral Epidemiology of Bronchiolitis After Nirsevimab Implementation and Respiratory Evolution in Infants

Launched by UNIVERSITY HOSPITAL, ROUEN · Oct 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a new treatment called Nirsevimab affects the viruses that cause acute bronchiolitis in infants. Acute bronchiolitis is a common respiratory illness in babies, often caused by the Respiratory Syncytial Virus (RSV). The trial aims to understand how Nirsevimab, which is given to infants under 12 months, changes the way these viruses spread during the upcoming illness seasons. Researchers will collect samples from infants diagnosed with bronchiolitis in emergency departments to see which viruses are present and how they impact the babies' health over time.

To participate, infants must be 12 months old or younger, and have their first episode of acute bronchiolitis while being treated in the pediatric emergency department during specific years (2024-2027). Parents will need to agree to have their baby’s nasal swab taken for testing. Throughout the study, the researchers will keep in touch with families over the phone for a year to monitor the infants' health and any potential breathing issues as they grow. This study is important for understanding the broader effects of Nirsevimab and how it might help reduce hospital visits for respiratory illnesses in young children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infant aged 12 months or less
• • Admitted to the pediatric emergencies services during one of the three epidemic years: 2024-2025, 2025-2026 and 2026-2027
• • With clinical diagnosis of first episode of acute bronchiolitis by the emergency pediatrician
• • With nasopharyngeal swab for virological diagnosis
• Exclusion Criteria:
• • Refusal of one or more of the infants parents to participate in the study
• • Infants parents refused to be called back for follow-up
• • No nasopharyngeal swab taken